Interleukin Genetics Plans to Continue Efforts to Out-License Intellectual
                                  Property

    WALTHAM, Mass., Sept. 4 /PRNewswire/ -- Interleukin Genetics,
Inc. (Amex: ILI), and Access Business Group International LLC, a division
of Alticor Inc., have reached an agreement that will increase access to all
intellectual property related to genetic tests jointly developed by
Interleukin Genetics and Access Business Group under their research
agreements. In turn, this will permit the expansion of Interleukin
Genetics' distribution network for such genetic tests. Under the agreement,
Access Business Group's existing license to the Interleukin Genetics'
intellectual property will become non-exclusive.

    Interleukin Genetics will have the right to brand, market, sell and
distribute all genetic tests developed using its existing and future
intellectual property, either itself or through additional third party
licensees. Access Business Group will continue to distribute the Heart
Health and General Nutrition genetic tests under the Gensona(R) brand name.
The agreement will continue to allow Interleukin Genetics to have exclusive
ownership of all inventions relating to genetic tests arising from research
programs between the companies.

    Lewis H. Bender, Chief Executive Officer at Interleukin Genetics,
commented, "This is an excellent agreement for Interleukin Genetics as we
now have the opportunity to aggressively pursue new partnerships for
distribution of the genetic tests and intellectual property created over
the years with our partner, Access Business Group. We are excited to
continue our current efforts to out-license our intellectual property to
companies in the biotechnology, molecular diagnostic, pharmaceutical,
direct sales and consumer products areas."

    About Interleukin Genetics

    Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused
personalized health company that develops preventive consumer products and
genetic tests for sale to the emerging personalized health market. Focused
on the future of health and medicine, Interleukin Genetics uses its leading
genetics research and scientific capabilities to develop and test
innovative preventive and therapeutic products. Interleukin Genetics
currently offers an array of Nutraceuticals and OTCeuticals(R), including
Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's
largest food, drug and mass retailers, and has commercialized genetic tests
for periodontal disease risk assessment, cardiovascular risk assessment,
and general nutrition assessment. Interleukin Genetics is headquartered in
Waltham, MA. For more information about Interleukin Genetics, its products
and ongoing programs, please visit http://www.ilgenetics.com.

    About Alticor and Access Business Group

    Alticor (http://www.alticor.com) is the parent company of Amway Corp., Quixtar
Inc., Access Business Group LLC and Alticor Corporate Enterprises.
Headquartered in Ada, Michigan, USA, Alticor and its affiliates offer
products, business opportunities, and product development, manufacturing
and logistic services in more than 80 countries and territories worldwide.
In its most recent financial year, the company reported worldwide sales of
more than $7.1 billion. For further information, please contact Alticor's
media information line at 616-787-7565 or e-mail Alticor's media relations
staff at mediainfo@alticor.com. Part of the Alticor family of companies,
Access Business Group is a team of vertically integrated
business-to-business experts. Access Business Group provides product
development, sourcing, manufacturing, printing, packaging and distribution.
Access Business Group offers expertise in nutrition, personal care, home
care and beauty.

    Certain statements contained herein are "forward-looking" statements
including statements regarding our ability to develop diagnostic,
personalized nutritional and therapeutic products to prevent or treat
diseases of inflammation and other genetic variations, our ability to
screen nutritional compounds for their effects on inflammatory responses
and other genetic variations, given specific genetic patterns and our
ability to make progress in advancing our core technologies. Because such
statements include risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements include,
but are not limited to, the risk of market acceptance of our products, the
risk of technology and product obsolescence, delays in product development,
the performance of our commercial partners, the availability of adequate
capital, the actions of our competitors and other competitive risks, and
those risks and uncertainties described in our annual reports on Form 10-K,
our quarterly reports on Form 10-Q and other documents we file with, or
furnish to, the Securities and Exchange Commission. We disclaim any
obligation or intention to update these forward-looking statements.